Barts Health NHS trust
London, United Kingdom
Location status: Recruiting
NCT Number: NCT05728359
The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
London, United Kingdom
Location status: Recruiting
This is a prospective observational cohort study in 8-10 cardiac centres across Europe. We will recruit patients presenting with acute myocardial infarction (AMI) and CS who are supported medically (n=100); with extracorporeal membrane oxygenation (n=50); and with the Impella Device (n=50). We will also enrol patients who present with either AMI and no evidence of CS (n=50) or CS due to non-ischaemic pathologies (e.g. myocarditis: n=50) as comparators. The recruitment target is 300 patients.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
CS will be defined by:
Exclusion criteria
Blood sampling and clinical data collection
Time frame: through study completion, an average of 5 days
This will be achieved through bloods sample collection, analysis and linked to the patient's clinical diagnosis and outcome.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Time frame: through study completion, an average of 5 days
Bloods samples will be collected from patients during their hospital stay and corresponding analysis performed.
Contact information is provided by the study sponsor or research team.
Alastair Proudfoot
CONTACT
Mervyn Andiapen
CONTACT
Barts & The London NHS Trust
Other
Prospective Observational Study Investigating Genomic Determinants of Outcome From Cardiogenic Shock (GOlDilOCS)
Acronym: Goldilocs
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07293923
Acute Myocardial Infarction (AMI), Cardiogenic Shock
Tbilisi, Georgia
View Trial DetailsNCT07656259
Cardio Vascular Disease, Cardiogenic Pulmonary Oedema
Rochester, Minnesota, United States
View Trial DetailsNCT05699005
Anemia, Cardiogenic Shock
Lille, NORD, France
View Trial DetailsNCT06308055
Cardiogenic Shock, Cardiovascular Diseases
Aachen, North Rhine-Westphalia, Germany
View Trial Details